Avenue therapeutics reports second quarter 2023 financial results and recent corporate highlights

- first patient dosed in phase 1b/2a clinical trial of aj201; topline data anticipated in first half of 2024 - - positive baer-101 preclinical data demonstrate excellent anti-seizure activity in translational animal model; phase 2a trial in epilepsy planned to initiate in 2024 - - agreement reached with u.s. fda on study design and analysis approach for phase 3 safety study of iv tramadol - miami, aug. 10, 2023 (globe newswire) -- avenue therapeutics, inc. (nasdaq: atxi) (“avenue” or the “company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the second quarter ended june 30, 2023. “avenue continues to make significant progress across our compelling pipeline of first- and best-in-class neurologic therapies for patients facing great unmet need," said alexandra maclean, m.d.
ATXI Ratings Summary
ATXI Quant Ranking